Analysis of taurolidine as a preventive solution for CIED infection: Preliminary results from a single centre
Objective: Cardiac implantable electronic device (CIED) infection is the most devastating adverse event related to any invasive CIED procedure. Our study investigates the adjunct use of a novel taurolidine containing antimicrobial solution during cardiac implantable electronic device placement to pr...
Saved in:
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Center for Scientific Research and Development of Education.
2025-01-01
|
Series: | Heart Vessels and Transplantation |
Subjects: | |
Online Access: | https://hvt-journal.com/articles/art538 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1841536293540986880 |
---|---|
author | Elkin Gonzales Villegas Alvaro Gilsanz José Romero Carmona |
author_facet | Elkin Gonzales Villegas Alvaro Gilsanz José Romero Carmona |
author_sort | Elkin Gonzales Villegas |
collection | DOAJ |
description | Objective: Cardiac implantable electronic device (CIED) infection is the most devastating adverse event related to any invasive CIED procedure. Our study investigates the adjunct use of a novel taurolidine containing antimicrobial solution during cardiac implantable electronic device placement to prevent cardiac implantable electronic device infection.
Methods: The authors prospectively evaluate all consecutive CIED procedures performed with adjunct use of the taurolidine containing antimicrobial adjunct in our centre. Cardiac implantable electronic device, procedure and patient related risk factors are recorded. Primary endpoint was major CIED infection. Patients were followed-up three months after implantation for acute CIED infections and one year after for subacute CIED infections.
Results: From September 2023 to January 2024, 26 high-risk CIED procedures were conducted with the taurolidine-based antimicrobial adjunct. Throughout the 3-month follow-up period, no infections were observed. Additionally, only one adverse event related to the CIED was recorded, with no adverse events of any severity related to the procedures or the antimicrobial adjunct, nor was any all-cause mortality reported during the follow-up period.
Conclusions: The use of the taurolidine containing antimicrobial adjunct for any CIED procedure is safe. No adverse event in relation could be recorded. |
format | Article |
id | doaj-art-e7dafd4649dc4853a525978011f4dba4 |
institution | Kabale University |
issn | 1694-7886 1694-7894 |
language | English |
publishDate | 2025-01-01 |
publisher | Center for Scientific Research and Development of Education. |
record_format | Article |
series | Heart Vessels and Transplantation |
spelling | doaj-art-e7dafd4649dc4853a525978011f4dba42025-01-14T17:00:55ZengCenter for Scientific Research and Development of Education.Heart Vessels and Transplantation1694-78861694-78942025-01-019110.24969/hvt.2024.538Analysis of taurolidine as a preventive solution for CIED infection: Preliminary results from a single centreElkin Gonzales Villegas0https://orcid.org/0000-0002-4128-4631Alvaro Gilsanz1José Romero Carmona2Department of Cardiovascular Surgery, University Hospital La Paz, Paseo de la Castellana, 261 - 28046 Madrid, SpainCentro de Biología Molecular Severo Ochoa (CSIC-UAM), Nicolás Cabrera 1, Campus de Cantoblanco, 28049 Madrid, SpainDepartment of Cardiovascular Surgery, University Hospital La Paz, Paseo de la Castellana, 261 - 28046 Madrid, SpainObjective: Cardiac implantable electronic device (CIED) infection is the most devastating adverse event related to any invasive CIED procedure. Our study investigates the adjunct use of a novel taurolidine containing antimicrobial solution during cardiac implantable electronic device placement to prevent cardiac implantable electronic device infection. Methods: The authors prospectively evaluate all consecutive CIED procedures performed with adjunct use of the taurolidine containing antimicrobial adjunct in our centre. Cardiac implantable electronic device, procedure and patient related risk factors are recorded. Primary endpoint was major CIED infection. Patients were followed-up three months after implantation for acute CIED infections and one year after for subacute CIED infections. Results: From September 2023 to January 2024, 26 high-risk CIED procedures were conducted with the taurolidine-based antimicrobial adjunct. Throughout the 3-month follow-up period, no infections were observed. Additionally, only one adverse event related to the CIED was recorded, with no adverse events of any severity related to the procedures or the antimicrobial adjunct, nor was any all-cause mortality reported during the follow-up period. Conclusions: The use of the taurolidine containing antimicrobial adjunct for any CIED procedure is safe. No adverse event in relation could be recorded.https://hvt-journal.com/articles/art538cardiac implantable electronic devicetaurolidine-containing antimicrobial adjuncttauropaceinfectioninfection prevention strategies |
spellingShingle | Elkin Gonzales Villegas Alvaro Gilsanz José Romero Carmona Analysis of taurolidine as a preventive solution for CIED infection: Preliminary results from a single centre Heart Vessels and Transplantation cardiac implantable electronic device taurolidine-containing antimicrobial adjunct tauropace infection infection prevention strategies |
title | Analysis of taurolidine as a preventive solution for CIED infection: Preliminary results from a single centre |
title_full | Analysis of taurolidine as a preventive solution for CIED infection: Preliminary results from a single centre |
title_fullStr | Analysis of taurolidine as a preventive solution for CIED infection: Preliminary results from a single centre |
title_full_unstemmed | Analysis of taurolidine as a preventive solution for CIED infection: Preliminary results from a single centre |
title_short | Analysis of taurolidine as a preventive solution for CIED infection: Preliminary results from a single centre |
title_sort | analysis of taurolidine as a preventive solution for cied infection preliminary results from a single centre |
topic | cardiac implantable electronic device taurolidine-containing antimicrobial adjunct tauropace infection infection prevention strategies |
url | https://hvt-journal.com/articles/art538 |
work_keys_str_mv | AT elkingonzalesvillegas analysisoftaurolidineasapreventivesolutionforciedinfectionpreliminaryresultsfromasinglecentre AT alvarogilsanz analysisoftaurolidineasapreventivesolutionforciedinfectionpreliminaryresultsfromasinglecentre AT joseromerocarmona analysisoftaurolidineasapreventivesolutionforciedinfectionpreliminaryresultsfromasinglecentre |